Shares of Eli Lilly & Co. LLY rose 1.16% to $993.64 Wednesday, on what proved to be an all-around positive trading session ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The possibility of adding a new Big Tech customer helped lift an American chipmaker's stock on Friday, Nov. 28, 2025, while a ...

Eli Lilly & Co, Cardinal Health Inc and Biogen Inc are among the top 10 performers in the S&P 500 since Oct 28, the last time ...

Wall Street's major averages closed in the green on Friday, as traders assessed fresh inflation data in hopes of gauging the Federal Reserve's monetary policy. The benchmark S&P 500 closed +0.2%, ...

Healthcare is the only one of the S&P 500's 11 sectors that is showing weakness on the day, with the Health Care Select ...

Eli Lilly ( LLY) shares clocked seven straight sessions of losses on Friday, as the stock was 0.5% lower at $1,009.15. The pharmaceutical giant lost 8% in the preceding six sessions. Overall, the ...

HSBC analyst Rajesh Kumar removed his reduce recommendation and upgraded S&P 500 component company Eli Lilly (NYSE: LLY) stock to hold with a $700 price target today. “Orforglipron’s ATTAIN-2 Phase 3 ...

Get the latest healthcare stock updates, key drug price negotiations, and policy changes impacting the S&P 500.

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

The S&P 500 closed near its Oct. 28 record, buoyed by optimism that the Federal Reserve could cut interest rates next month.

The S&P 500 is back within spitting distance of an all-time high, and this time Big Tech isn’t leading the rebound.